Expanding Aseptic Fill-Finish Capacity
The demand for fill finish manufacturing continues to grow due to the rising number of biologics and gene therapy products being developed, predominantly for parenteral administration. The increasing introduction of more convenient and user-friendly routes of administration for these products, such as semaglutides, has also significantly contributed to the demand for more manufacturing capacity.
Pace® Life Sciences understands the underlying market drivers influencing our clients’ advancements which informs our latest investments to expand aseptic filling contract manufacturing capabilities in Salem, NH. We specialize in producing clinical materials with agility and customization spanning dosage forms, batch sizes and available API. Our structure for clinical phase manufacturing and testing services is suited to support clients requiring more modest, although often more complex, clinical batches as part of our aim to provide consistent, high-quality services from end-to-end to our primary client base.
The upcoming completion of an expansion to our Salem, NH facility will establish the site as a Center of Excellence for Aseptic Fill-Finish processing. The addition of our isolated vial filling line enables state-of-the-art clinical supplies manufacturing with the highest level of sterility assurance and EU Annex 1 compliance. This fill line, plus other facility enhancements, positions us to provide industry-leading service to our clients requiring cGMP manufacturing in the injectable space for vaccines, gene therapies, antibodies, and protein-based therapeutics. With expansions to both manual and automated fill-finish manufacturing capabilities, we aim to scale alongside our clients as their program evolves and regulatory expectations advance so they are successfully equipped across all clinical phases.
